Metabolic Reprogramming as an Exploitable Vulnerability in NSCLC

Dear Colleague, 

NSCLC still represents one of the most frequent and deadliest cancers in the world. It is a heterogeneous disease, with multiple different oncogenic driver mutations representing potential therapeutic targets. Despite the approval of targeted therapies and immune-checkpoint inhibitors, which significantly improved non small cell lung cancer (NSCLC) patient survival, a significant proportion of patients cannot benefit from these treatments. These include patients with KRAS and LKB1/STK11 mutations. Among NSCLCs, these tumors are among those with the worst prognosis. Both KRAS and LKB1 gene products play a pivotal role in metabolic reprogramming and nutrient sensing. The metabolic alterations present in KRAS/LKB1 mutated NSCLC could, however, represent a vulnerable point of these tumors opening the possibility to combine chemotherapy with drugs interfering with cell metabolism.  

This Special Issue aims to increase the knowledge of the metabolic alterations of these tumors and in optimizing combination treatments which could help in ameliorating the prognosis of this group of NSCLC patients.

Dr. Massimo Broggini
Guest Editor
Dr. Elisa Caiola
Co-Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.